Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EPS (Weighted Average and Diluted) (2016 - 2025)

Altimmune (ALT) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.26 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 21.21% to -$0.26 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.0 through Dec 2025, up 25.37% year-over-year, with the annual reading at -$1.0 for FY2025, 25.37% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.26 at Altimmune, down from -$0.21 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.21 in Q3 2025, with the low at -$0.81 in Q3 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.41, with a median of -$0.38 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 229.41% in 2021, then surged 41.07% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.56 in 2021, then grew by 21.43% to -$0.44 in 2022, then dropped by 27.27% to -$0.56 in 2023, then skyrocketed by 41.07% to -$0.33 in 2024, then grew by 21.21% to -$0.26 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.26, -$0.21, and -$0.27 for Q4 2025, Q3 2025, and Q2 2025 respectively.